Zennova Pharma Group Completes Tens of Millions RMB Series A Financing to Accelerate New Drug Development in Four Key Therapeutic Areas

On August 23, 「Zennova」, a portfolio company of 「Sichuan Venture Capital」, announced the completion of its Series A financing round, raising tens of millions of RMB. The proceeds from this round will be primarily used to accelerate the development of the company's pharmaceutical products in the fields of ophthalmology, oncology, antiviral therapy, and cardiovascular diseases.

「Zennova」 in 2018 inChengdu High-tech ZoneFollowing its official establishment, its founder, Mr. Guo Dahai, possesses over 25 years of multinational management experience in the pharmaceutical industry and a proven track record of multiple successful entrepreneurial ventures both domestically and internationally, having spearheaded the U.S. approval and commercial launch of dozens of New Drug Application (NDA) and Abbreviated New Drug Application (ANDA) products. Core team members of the company hail from world-renowned pharmaceutical enterprises such as 「Roche」, 「Merck & Co.」, and 「Teva」, and have assembled a top-tier international core team through a joint operational model spanning China and the United States. In September 2018, 「Sichuan Venture Capital」, as the lead investor in the angel round financing of 「Zennova」, invested tens of millions of RMB in 「Zennova」. Through an investment-driven attraction mechanism, it facilitated the settlement and development of 「Zennova」 in the Chengdu High-Tech Zone. Subsequently, it provided multi-dimensional post-investment value-added services to 「Zennova」, including but not limited to policy coordination, brand promotion, financing matchmaking, and customized services, thereby supporting and witnessing the rapid growth of 「Zennova」.

Since its establishment, 「Zennova」 has consistently prioritized strengthening its R&D capabilities, accelerating the development pipeline of its new products, and expediting the commercialization of its product portfolio, with a steadfast commitment to delivering products of superior value to patients worldwide. To date, 「Zennova」 has over ten pipeline candidates. Its core blockbuster product is expected to obtain FDA approval in the United States in 2022 and be launched for commercial sale in the U.S. market. Following this, a series of new products will be introduced to fill gaps in China, benefiting patients both in China and overseas. Furthermore, 「Zennova」's manufacturing and R&D facility in Chengdu High-tech Zone, which complies with U.S. FDA and EU standards, has completed its first-phase construction covering 30,000 square meters, laying a solid foundation for the company's sustained and rapid long-term growth.

Following this round of financing, 「Zennova」 will leverage its strengths in product development and design, international operations, global investment and financing, and the establishment of international quality standards to strategically focus on high-barrier ophthalmic products, as well as therapeutic areas including oncology, antivirals, and cardiovascular diseases, thereby establishing core competitive advantages in the R&D and translation of high-end pharmaceuticals.

To date, 「Sichuan Venture Capital」 has invested in the biopharmaceutical sector, including 「Kintor Pharmaceutical(09939.HK)"], "Mediccon", "Antigen", "Hibio Pharmaceuticals", "Zennova", "Haifeng Biotech", "Zhishan Weixin Biotech", "Majesticell", "Huajian Future", "Jingze Biotech", and "Ruimu Biotech", encompassing dozens of industry-leading companies. Furthermore, for many of the aforementioned enterprises, "Sichuan Venture Capital" served as the sole investor in their angel financing rounds.

In the future, 「Sichuan Venture Capital」 will continue to leverage its accumulated advantages in biomedicine, electronic information, and intelligent manufacturing. By continuously deepening its industry expertise and precisely empowering enterprises, it will contribute the strength of its fund to the high-quality economic development of Sichuan Province and Chengdu City.

About 「Zennova」

Zennova Pharmaceuticals Group is a Cayman-registered, innovation-driven high-tech international pharmaceutical group. Leveraging exceptional product development capabilities and global operational expertise, the Company delivers products of superior value to patients. Anchored by three strategic pillars—China-based manufacturing, global R&D, and global market expansion—Zennova focuses on four key therapeutic areas: ophthalmology, antiviral therapies, cardiovascular diseases, and oncology, with ophthalmology and oncology serving as its two core strategic focuses. Currently, multiple innovative formulations are undergoing early-stage clinical trials in both China and the United States.

The company currently maintains R&D and manufacturing bases in New York, USA, and Chengdu, China. Among them, the pharmaceutical manufacturing base located in the Chengdu Tianfu International Bio-city will, in the future, obtain certification from the U.S. FDA, EU EMA, and China GMP, achieving internationally advanced quality standards. It will produce a comprehensive range of dosage forms that comply with European and American quality standards and bioequivalence requirements, including various prescription drugs such as multiple anti-tumor medications, sterile eye drops, and central nervous system (CNS) agents. These products will be marketed in China and globally.